Navigation Links
Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
Date:6/17/2008

Dr. Farkad Ezzet Will Present on the Strategic Value of Literature Modeling to Assess Disease Progression and Drug Attributes in Clinical Development

MOUNTAIN VIEW, Calif., June 17 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Farkad Ezzet, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to speak to members of the biotechnology and pharmaceutical industries attending the 2008 AAPS National Biotechnology Conference. The Congress will be held at the Metro Toronto Convention Center in Toronto, Canada from June 22-25, 2008. Dr. Ezzet will present on June 24, joining other leading industry experts in a roundtable session on the utilization of disease progression models in clinical drug development.

Dr. Ezzet's presentation, entitled "The Role of Literature-Based Disease Progression Models to Support Knowledge Management and Decision-Making in Clinical Drug Development," will describe how model-based approaches that incorporate public-source data from the scientific literature can provide quantitative insights into disease progression and predictive assessments of a new drug candidate's likely product profile versus competing treatments. Dr. Ezzet's presentation will feature an illustrative case study for the treatment of obesity, and will also cover important considerations for using literature-based modeling approaches to enhance strategic decision-making in drug development.

"Literature-based models provide a quantitative assessment of the competitive landscape and offer a framework to address important clinical development program questions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Public domain information and data can be leveraged to develop candidate disease models, to measure the performance of established treatments across target therapeutic areas, and to help predict the likely clinical profile of early-stage development compounds. Pharsight is pleased to participate at the AAPS roundtable session, and we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to enhance drug development decision-making."

Further information can be found at http://www.aapspharmaceutica.com/meetings/biotec/bt08.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight Hosts European PKS User Meeting
2. Pharsight Achieves $7.6 Million In Quarterly Revenue
3. Pharsight Signs Two New DMX(R) License Customers
4. Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
5. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
6. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
7. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
8. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
9. Pharsight Achieves $7.4 Million in Quarterly Revenue
10. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
11. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):